Hanmi Pharm Overview

  • Year Founded
  • 1973

Year Founded

  • Status
  • Public

  • Employees
  • 2,400

Employees

  • Stock Symbol
  • 128940

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $336.68
  • (As of Friday Closing)

Hanmi Pharm General Information

Description

Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and raw materials for medicines. The company makes strenuous and enthusiastic efforts to develop treatments for diabetes, obesity, cancer, autoimmune and rare disease to keep everyone's health and improve their quality of life. The group distributes its products within Korean market and to overseas markets.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • 14, Wiryeseong-daero
  • Songpa
  • Seoul, Gyeonggi 05545
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
KRX
Corporate Office
  • 14, Wiryeseong-daero
  • Songpa
  • Seoul, Gyeonggi 05545
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hanmi Pharm Stock Performance

As of 20-Nov-2026, Hanmi Pharm’s stock price is $336.68. Its current market cap is $4.28B with 12.7M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$336.68 $316.72 $207.54 - $448.00 $4.28B 12.7M 152K $10.21

Hanmi Pharm Financials Summary

As of 30-Sep-2026, Hanmi Pharm has a trailing 12-month revenue of $1.14B.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 4,829,031 4,244,969 2,730,571 3,805,905
Revenue 1,144,557 1,087,408 1,096,058 1,140,302
EBITDA 240,678 226,266 210,558 241,930
Net Income 129,594 119,141 88,912 111,845
Total Assets 1,624,287 1,484,433 1,371,949 1,473,344
Total Debt 284,755 301,534 337,201 444,538
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Hanmi Pharm Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hanmi Pharm‘s full profile, request access.

Request a free trial

Hanmi Pharm Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Hanmi Pharm Co Ltd is a Korea-based company, engaged in manufacturing and marketing of medicines, medical supplies and r
Biotechnology
Seoul, South Korea
2,400 As of 2025

Seoul, South Korea
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Hanmi Pharm Competitors (14)

One of Hanmi Pharm’s 14 competitors is Yuhan, a Corporation company based in Seoul, South Korea.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Yuhan Corporation Seoul, South Korea
Genentech Formerly VC-backed South San Francisco, CA
Merck & Co. Corporation Rahway, NJ
GSK Corporation London, United Kingdom
Celltrion Formerly VC-backed Incheon, South Korea
You’re viewing 5 of 14 competitors. Get the full list »

Hanmi Pharm Patents

Hanmi Pharm Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026235366-A1 Messenger ribonucleic acid encoding analogs of p53 protein, and medical uses thereof Pending 09-May-2025
WO-2026212360-A1 Modified sting protein, nucleic acid encoding same, and use thereof Pending 02-Apr-2025
WO-2026142281-A1 Therapeutic agent for gastroesophageal reflux disease with improved dosing convenience using water-insoluble polymer Pending 23-Dec-2024
WO-2026135347-A1 Ep300 protein degrader and use thereof Pending 20-Dec-2024
WO-2026135298-A1 Liposome composition for oral administration comprising glp-1 analog and method for preparing same Pending 20-Dec-2024 A61K9/127
To view Hanmi Pharm’s complete patent history, request access »

Hanmi Pharm Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hanmi Pharm Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hanmi Pharm‘s full profile, request access.

Request a free trial

Hanmi Pharm Investments & Acquisitions (7)

Hanmi Pharm’s most recent deal was a Merger/Acquisition with Aptose Biosciences for . The deal was made on 30-Jun-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Aptose Biosciences 30-Jun-2026 Merger/Acquisition Drug Discovery
Aptose Biosciences 31-Jan-2024 PIPE Drug Discovery
Darmiyan 10-Apr-2020 Seed Round Decision/Risk Analysis
Tomocube 29-Mar-2016 Early Stage VC Diagnostic Equipment
Allegro Ophthalmics 26-Jan-2015 Later Stage VC Drug Discovery
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Hanmi Pharm ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

30.29 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Hanmi Pharm’s complete esg history, request access »

Hanmi Pharm Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Aptose Biosciences Toronto, Canada 1986
Hanmi Pharm (Global Rights to HM17321) Seoul, South Korea

Hanmi Pharm FAQs

  • When was Hanmi Pharm founded?

    Hanmi Pharm was founded in 1973.

  • Where is Hanmi Pharm headquartered?

    Hanmi Pharm is headquartered in Seoul, South Korea.

  • What is the size of Hanmi Pharm?

    Hanmi Pharm has 2,400 total employees.

  • What industry is Hanmi Pharm in?

    Hanmi Pharm’s primary industry is Biotechnology.

  • Is Hanmi Pharm a private or public company?

    Hanmi Pharm is a Public company.

  • What is Hanmi Pharm’s stock symbol?

    The ticker symbol for Hanmi Pharm is 128940.

  • What is the current stock price of Hanmi Pharm?

    As of 20-Nov-2026 the stock price of Hanmi Pharm is $336.68.

  • What is the current market cap of Hanmi Pharm?

    The current market capitalization of Hanmi Pharm is $4.28B.

  • What is Hanmi Pharm’s current revenue?

    The trailing twelve month revenue for Hanmi Pharm is $1.14B.

  • Who are Hanmi Pharm’s competitors?

    Yuhan, Genentech, Merck & Co., GSK, and Celltrion are some of the 14 competitors of Hanmi Pharm.

  • What is Hanmi Pharm’s annual earnings per share (EPS)?

    Hanmi Pharm’s EPS for 12 months was $10.21.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process